
Opinion|Videos|March 4, 2025
Third-Line Treatments and Current Practice Guidelines in Advanced RCC
Author(s)Pedro Barata, MD, MSc, FACP
A panelist discusses how, based on the NCCN guidelines for kidney cancer, third-line treatment options for this patient include cabozantinib, lenvatinib plus everolimus, tivozanib, and everolimus monotherapy. Clinical trials and best supportive care remain important considerations at this stage.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What are the third-line options for this patient per the NCCN guidelines for kidney cancer?
Advertisement
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Does Not Approve Ivonescimab for EGFR-Mutant NSCLC
2
Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETs
3
FDA Approves Durvalumab-EV Combo, Expanding MIBC Treatment Options
4
Crossover to Bezuclastinib Plus Sunitinib Improves Disease Control in Pretreated GIST
5

